Opportunity Alert: MIV Therapeutics
| From Name: |
Trilogy Capital Partners |
| From Address: |
tcp@olas72.greatoffersforyou.net |
| Date Received: |
04/08/2005 - 11:00:03 am |
| Spam Score: |
11.7 |
| Category: |
Investment |
View Spam Assassin Report :: Add/View Comments |
Email Preview:
MAJOR ANNOUNCEMENT: BIPH (OTC BB: BIPH) CLICK THE LINKS
BELOW FOR MIV THERAPEUTICS INFORMATION: Today we are pleased to
introduce MIV Therapeutics, one of our newest Portfolio Clients. Please
take a moment to click the links above to learn more about this
exciting company and potential market success story. [...]
|
Email Message:
Return-Path:
Received: from olas72.greatoffersforyou.net ([199.227.253.72])
by admin.domain.com (8.12.3/8.12.3/Debian-7.1) with ESMTP id j38F3Lpl029205
for ; Fri, 8 Apr 2005 10:03:22 -0500
From: "Trilogy Capital Partners"
To: "Recipient@domain.com"
Reply-To: "Trilogy Capital Partners"
Date: Fri, 08 Apr 2005 11:03:22 -0400
Importance: Normal
Message-ID:
Subject: Opportunity Alert: MIV Therapeutics
Mime-Version: 1.0
Content-Type: text/html; charset="us-ascii"
MAJOR ANNOUNCEMENT: BIPH (OTC BB: BIPH)
CLICK THE LINKS BELOW FOR MIV THERAPEUTICS INFORMATION:Today we are pleased to introduce MIV Therapeutics, one of our newest Portfolio Clients. Please take a moment to click the links above to learn more about this exciting company and potential market success story.
Sincerely,
The Editors
Trilogy Capital PartnersMIV Therapeutics Expands Intellectucal Property for
Multi-layer/Multi-drug Delivery Systems with
Two New Patent Applications
_______________________
MIV Patent Applications Describe Novel Biocompatible Coatings
for Implantable Medical Devices(press release continues below)
VANCOUVER, B.C.—April 7, 2005 -- MIV Therapeutics, Inc. (OTCBB: MIVT) a developer of next-generation biocompatible coatings and drug delivery technologies, has filed two new patent applications that will enable the development and manufacture of an advanced new class of drug eluting coatings capable of delivering multiple medicines from a cardiovascular stent or other implanted medical devices. The new patent applications expand MIVT's proprietary biocompatible coating technology platform, upon which the Company is developing a line of advanced stents that are expected to offer improved therapeutic functionality and patient health.
"Our proprietary intellectual property has received a tremendous boost," said Alan Lindsay, Chairman and CEO of MIVT. "The new MIVT patent applications represent significant growth potential within the multi-billion-dollar marketplace for advanced, drug-eluting cardiovascular stents. Both inventions, which were developed specifically for multi-layer/multi-drug delivery systems, offer the extra flexibility of drug release profiles combined with the superb biocompatibility of an underlying hydroxyapatite nano-layer. This extremely valuable intellectual property belongs exclusively to MIV Therapeutics and is not subject to licensing agreements with any third party. The patent applications focus on the uniqueness of our coating technologies, which are maturing quickly on their way to commercialization. We are dedicated to bringing these technologies to the market in an efficient manner, and we've already taken decisive steps in this direction."The newly-filed patent applications were developed entirely by the MIVT team at the MIVI Technologies Inc. research and development laboratories in Vancouver , B.C. They include:
- "A Multilayer Drug Delivery System and Method of Manufacturing Same." This patent application describes a unique multi-layer composite coating developed with focus on drug delivery applications. This novel technology may be used "as is" or in combination with biodegradable polymers. It can be applied successfully to cardiovascular stents, as well as other implantable medical devices.- "A Method of Modifying a Metal Substrate to Improve Surface Coverage of a Coating." The patent application describes a method of surface preparation of a metal substrate to without requiring high temperature treatment, which may irreversibly alter mechanical properties of the substrate.
The MIVT patent applications also cover the application of multilayer drug-eluting coatings for a broad range of implantable medical devices, in addition to cardiovascular stents.
Dr. Dean-Mo Liu
, Ph.D., MIVT's Director of Drug Delivery Technologies added, "The unique formulation of our advanced coating offers an opportunity to apply these versatile multilayer coatings to a broad range of implantable medical devices capable of retaining multiple drugs and releasing them in a predictable, controlled fashion, over a prolonged period of time. Our technology guarantees drug encapsulation and release in a manner which, in our opinion, offers clear advantages over other biocompatible coatings that have been already released to the market or are under development by our competitors."
About MIV Therapeutics
MIVT has secured the exclusive worldwide license from the
University
of
British Columbia to use and sublicense three patents for proprietary HAp coating technologies, including their application for the development, manufacture and sale of coated stents and other implantable medical devices. The above patent applications represent inventions developed internally and wholly owned by MIV Therapeutics Inc.
MIV Therapeutics is developing a next generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIVT's ultra-thin coating has been derived from a unique biocompatible material called hydroxyapatite (HAp) that demonstrated during in-vivo animal trials excellent safety and superior healing properties pursued by the medical science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. MIVT reached a Collaborative Research Agreement (CRA) with the
University
of
British Columbia and received a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the additional development of hydroxyapatite as a drug eluting coating. MIVT's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. The Company has progressed to the next development stage, which is expected to finalize the drug-eluting research and development program. Recently MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP).
Under this sponsorship the Company will progress to the next development stage, which is expected to finalize the drug-eluting research and development program. For more information, please visit http://www.mivtherapeutics.com.
To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html.
To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe", "will", "breakthrough", "significant", "indicated", "feel", "revolutionary", "should", "ideal", "extremely" and "excited". These statements are made under "
Safe Harbor " provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.Contact:
MIV Therapeutics Inc.
Investors:
Dan Savino, 800-221-5108 ext.16
604-301-9546 (fax)
dsavino@mivi.caor
Trilogy Capital Partners
Investors:
Paul Karon, 800-342-1467
paul@trilogy-capital.comor
Product inquiries and business opportunities:
Arc Rajtar, 604-301-9545 ext.22
arajtar@mivi.caCompensation and Other Disclosures
This Stock Alert (the "Alert") is published by Trilogy Capital Partners, Inc. ("Trilogy") to provide readers with information on selected publicly traded companies. Factual information is obtained from public filings and other sources deemed to be reliable; however, Trilogy takes no responsibility for verifying the accuracy of such information and makes no representation that such information is accurate or complete. Certain of the statements in this Alert may be considered forwarded looking statements. Trilogy makes no representation and provides no assurance or guaranty that such forward looking statements will be prove to be accurate. Statements of opinion and belief are those of the authors and/or editors of this Alert, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the company or companies profiled or any particular expertise in the industries or markets in which the profiled company or companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of profiled company or companies. Neither Trilogy nor anyone involved in the publication of this Alert is a registered investment adviser or broker/dealer. Trilogy makes no recommendation that the purchase of securities of company or companies profiled in this Alert are suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the company or companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. An investor in such securities should be prepared and able to bear a loss of his or her entire investment. Nothing in this Alert should be construed as an offer or solicitation to buy or sell any securities of any profiled company. Tril!
ogy has been retained to provide investor relations services for the company profiled in this Alert and receives compensation for those services. Further, Trilogy and its employees and affiliates may own, or may purchase and sell, securities of the company or companies profiled. Trilogy undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled company or companies. Trilogy has the following compensation arrangements with the company or companies profiled in this Alert: MIV Therapeutics: $10,000 per month through November 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. Trilogy hasnon-transferable warrants from this company to purchase 2,720,000 shares of common stock for $0.26 per share and expiring in November 2007, provided that Trilogy may not exercise the warrants to the extent that following such exercise Trilogy would beneficially own 5% or more or the outstanding common stock of this company.
Compensation and Other Disclosures
The content of this message is published by MIV Therapeutics and sent to select email lists through Lake Group Media, Inc. ("Lake") to provide readers with information on selected publicly traded companies. Factual information is obtained from public filings and other sources deemed to be reliable; however, neither MIV Therapeutics nor Lake takes responsibility for verifying the accuracy of such information and they make no representation that such information is accurate or complete. Certain of the statements in this Update may be considered forwarded looking statements. MIV Therapeutics and Lake make no representation and provide no assurance or guaranty that such forward looking statements will prove to be accurate. See the companies filings with the Securities and Exchange Commission for factors that may cause results to be significantly different. Statements of opinion and belief are those of the authors and/or editors of this Update, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the company or companies profiled or any particular expertise in the industries or markets in which the profiled company or companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of the profiled company or companies. Neither MIV Therapeutics, Lake, nor anyone involved in the publication or dissemination of this Update is a registered investment adviser or broker/dealer. MIV Therapeutics and Lake make no recommendation that the purchase of securities of the company or companies profiled in this Update are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the company or companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. An !
investor in such securities should be prepared and able to bear a loss of his or her entire investment. Nothing in this Update should be construed as an offer or solicitation to buy or sell any securities of any profiled company. Lake has been retained to provide direct marketing services for the company profiled in this Update and receives compensation for those services. Further, Lake and its employees and affiliates may own, or may purchase and sell, securities of the company or companies profiled. Lake undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled company or companies. Lake has the following compensation arrangements with the company or companies profiled in this Update:Lake & Inet receive a commission (fee) ranging from $1,000 to $25,000 for each direct marketing list recommended and ordered for the dissemination of this Update.
This is an advertisement.
Your address was obtained from I-NetValues or one of its affiliates.
To discontinue subscription, please go here. To remove by postal mail:
1730 South Federal Highway Suite 115
Delray Beach, Florida 33483
|
Spam Assassin Report:
0.9 FROM_OFFERS From address is "at something-offers"
0.5 TO_ADDRESS_EQ_REAL To: repeats address as real name
0.6 NO_OBLIGATION BODY: There is no obligation
1.8 STOCK_ALERT BODY: Offers a alert about a stock
0.3 URI_OFFERS URI: Message has link to company offers
0.1 HTML_30_40 BODY: Message is 30% to 40% HTML
0.4 HTML_LINK_PUSH_HERE BODY: HTML link text says "push here" or similar
1.5 RAZOR2_CF_RANGE_51_100 BODY: Razor2 gives confidence level above 50%
[cf: 100]
1.2 MIME_HTML_ONLY BODY: Message only has text/html MIME parts
0.0 HTML_MESSAGE BODY: HTML included in message
0.2 HTML_FONT_BIG BODY: HTML tag for a big font size
0.1 RAZOR2_CHECK Listed in Razor2 (http://razor.sf.net/)
0.1 DNS_FROM_AHBL_RHSBL RBL: From: sender listed in dnsbl.ahbl.org
1.1 RCVD_IN_SBL RBL: Received via a relay in Spamhaus SBL
[199.227.253.72 listed in sbl-xbl.spamhaus.org]
0.6 URIBL_SBL Contains an URL listed in the SBL blocklist
[URIs: newconsumeroffers.com]
0.5 URIBL_WS_SURBL Contains an URL listed in the WS SURBL blocklist
[URIs: newconsumeroffers.com]
2.0 URIBL_OB_SURBL Contains an URL listed in the OB SURBL blocklist
[URIs: newconsumeroffers.com]
|
No Comments Posted Yet
Add your comment below! |
>> Add A Comment:
|
Spam Reg Home